Companies

OS Therapies Inc (OSTX) SEC filings

CIK 0001795091 · Pharmaceutical Preparations (SIC 2834) · NYSE · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024
Net income (USD)-28.8 M-7.8 M
Diluted EPS (USD/shares)-0.98-1.46

Latest filings

FiledFormDescriptionPeriod
2026-10-198-KCURRENT REPORT items 1.01,3.02,8.01,9.012026-10-15
2026-10-05332026-09-29
2026-10-05332026-09-29
2026-10-058-KCURRENT REPORT items 1.01,5.02,8.01,9.012026-09-29
2026-09-21S-8REGISTRATION STATEMENT
2026-09-108-KCURRENT REPORT items 8.01,9.012026-09-10
2026-09-10424B7PROSPECTUS SUPPLEMENT
2026-09-098-KCURRENT REPORT items 5.02,5.07,9.012026-09-09
2026-08-25DD items 06b
2026-08-218-KCURRENT REPORT items 1.01,9.012026-08-21
2026-08-21424B5PROSPECTUS SUPPLEMENT
2026-08-1410-QQUARTERLY REPORT2026-06-30
2026-08-128-KCURRENT REPORT items 1.01,2.03,3.02,9.012026-08-06
2026-08-068-KCURRENT REPORT items 1.01,2.03,3.02,9.012026-07-31
2026-08-06424B5PROSPECTUS SUPPLEMENT
2026-07-298-KCURRENT REPORT items 1.022026-07-23
2026-07-24ARSARS2025-12-31
2026-07-24DEFA14ADEFINITIVE ADDITIONAL MATERIALS
2026-07-24DEF 14APROXY STATEMENT2026-09-09
2026-07-23332026-07-01
2026-07-16DD items 06b
2026-07-078-K/AAMENDMENT NO. 1 TO FORM 8-K items 9.012026-06-30
2026-07-028-KCURRENT REPORT items 1.01,2.03,3.02,5.02,8.01,9.012026-06-30
2026-05-1810-QQUARTERLY REPORT2026-03-31
2026-05-155/A5/A2024-12-31

Forms on file (last 1,000): 8-K 40, CORRESP 31, 4 26, 3 14, D 12, UPLOAD 10, EFFECT 9, S-1/A 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=OSTX (0.002 USD), /gw/filings/filings?ticker=OSTX&form=8-K, /gw/filings/facts?ticker=OSTX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange